This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Elicio Therapeutics Stock (NASDAQ:ELTX) 30 days 90 days 365 days Advanced Chart Get Elicio Therapeutics alerts:Sign Up Key Stats Today's Range$10.20▼$10.3650-Day Range N/A52-Week Range N/AVolume61,887 shsAverage Volume142,069 shsMarket Capitalization$168.96 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y. Read More Elicio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreELTX MarketRank™: Elicio Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 774th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingElicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageElicio Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Elicio Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 94.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.12% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Elicio Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.12% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Elicio Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for ELTX on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTX Stock News HeadlinesElicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant ...August 13, 2025 | finance.yahoo.comElicio Therapeutics Publishes Promising Phase 1 Study DataAugust 12, 2025 | msn.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 dataAugust 12, 2025 | msn.comElicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage PatientsAugust 12, 2025 | globenewswire.comElicio Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comElicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 8, 2025 | finanznachrichten.deElicio Therapeutics: Q2 Earnings SnapshotAugust 8, 2025 | chron.comSee More Headlines ELTX Stock Analysis - Frequently Asked Questions How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.03. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Top institutional investors of Elicio Therapeutics include Geode Capital Management LLC (0.76%), Mayflower Financial Advisors LLC (0.06%) and Raymond James Financial Inc. (0.04%). View institutional ownership trends. What other stocks do shareholders of Elicio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA). Company Calendar Last Earnings8/07/2025Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:ELTX CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Elicio Therapeutics$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+25.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($6.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.90 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-175.83% Debt Debt-to-Equity Ratio5.09 Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$2.30 million Price / Sales73.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book94.36Miscellaneous Outstanding Shares16,340,000Free Float8,022,000Market Cap$169.61 million OptionableNot Optionable Beta1.18 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ELTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.